pubrio
Neurizon

Neurizon

Australia · Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Neurizon Therapeutics is dedicated to revolutionizing the treatment of neurodegenerative diseases. With a focus on optimizing quality of life for patients, the company is pioneering novel applications for NUZ-001 (S-Monepantel). After a decade of research and development, promising results in preclinical and clinical studies have been achieved, particularly in the treatment of Amyotrophic Lateral Sclerosis (ALS). Neurizon is committed to bringing transformative treatments to patients as quickly as possible, with ongoing trials and partnerships aimed at accelerating approval and global launch.

Company Insights
Company Overview

2000

Founded

Research

Industry

Australia

Location

7,655,678

Ranking

11 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Neurizon

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​